Acute Lymphoblastic Leukemia Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Adaptive Variable-Resistance Training in Pediatric Survivors of Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia Interventions: Other: Adaptive variable-resistance training; Other: Standard physical therapy Sponsors: Cairo University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.
Conditions: Acute Lymphoblastic Leukemia, Pediatric Interventions: Diagnostic Test: lncRNA signature analyses Sponsors: IRCCS SYNLAB SDN; SANTOBONO PAUSILIPON CHILDREN HOSPITAL Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2024 Category: Research Source Type: clinical trials

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
Conditions: B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse Interventions: Drug: Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy Sponsors: Beijing GoBroad Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence
Conditions: Acute Lymphoblastic Leukemia Interventions: Other: Best Practice; Procedure: Biospecimen Collection; Other: Electronic Health Record Review; Other: Interview; Other: Medical Device Usage and Evaluation; Other: Medical Device Usage and Evaluation; Other: Survey Administration Sponsors: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Conditions: Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia Interventions: Drug: Asparaginase Erwinia chrysanthemi; Procedure: Biospecimen Collection; Biological: Blinatumomab; Procedure: Bone Marrow Aspiration; Drug: Calaspargase Pegol; Procedure: Computed Tomography; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin; Drug: Dexamethasone; Drug: Doxorubicin; Procedure: Echocardiography; Procedure: FDG-Positron Emission Tomography; Drug: Leucovorin; Procedure: Lumbar Puncture; Procedure: Magnetic Resonance Imaging; Drug: Mercaptopurine; Drug: Methotrexate; Procedure: Multigated Acquisition Sca...
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Conditions: T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia Interventions: Drug: Autologous CD5 CAR T-cells; Drug: Previous SCT donor-derived CD5 CAR T-cells; Drug: Newly matched donor-derived CD5 CAR T-cells Sponsors: Beijing GoBroad Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Conditions: T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia Interventions: Drug: Autologous CD5 CAR T-cells; Drug: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells; Drug: Newly matched donor-derived CD5 CAR T-cells Sponsors: Beijing GoBroad Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma
Conditions: T-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia Interventions: Drug: Autologous CD7 CAR T-cell; Drug: Prior-HSCT donor-derived CD7 CAR T-cell; Drug: New donor-derived CD7 CAR T-cell Sponsors: Beijing GoBroad Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome-Positive; Acute Lymphoblastic Leukemia Interventions: Drug: Blinatumomab; Drug: Asciminib Sponsors: M.D. Anderson Cancer Center; Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials

PTCy and ATG for MSD and MUD Transplants
Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Hodgkin Lymphoma; Non-hodgkin Lymphoma Interventions: Drug: ATG 5.0; Drug: Cyclophosphamide injection; Drug: ATG 2.5 ±1.5 Sponsors: Instituto Nacional de Cancer, Brazil Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Conditions: Acute Lymphoblastic Leukemia; Lymphoblastic Lymphoma; Mixed Phenotype Acute Leukemia Interventions: Drug: Dexamethasone; Drug: Vincristine; Drug: Daunorubicin; Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine); Drug: Methotrexate; Drug: Cytarabine Sponsors: St. Jude Children ' s Research Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

Raman Spectroscopy Compared to Flow Cytometry
Conditions: Acute Lymphoblastic Leukemia Interventions: Diagnostic Test: Raman spectroscopy Sponsors: Hospital Regional de Alta Especialidad del Bajio; Optics research center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome Interventions: Biological: Actinium Ac 225-DOTA-Daratumumab; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Biological: Daratumumab; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Hematopoietic Cell Transplantation; Biological: Indium In 111-DOTA-Daratumumab; Drug: Melphalan; Procedure: Multigated Acquisition Scan; Procedure: Radionuclide Imaging; Procedure: Single Photon Emission Computed Tomography; Drug: Sirolimus; Drug: Tacrolimus; R...
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Conditions: Philadelphia-Negative ALL; Philadelphia-Positive ALL; Relapsed ALL, Adult; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia (ALL); Refractory Acute Lymphoid Leukemia in Relapse Interventions: Biological: 19-28z/IL-18 CAR T cells Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Conditions: Acute Lymphoblastic Leukemia; Non-hodgkin Lymphoma Interventions: Drug: Metabolically Armed CD19 CAR-T cells Sponsors: Anhui Provincial Hospital; Leman Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials